Mechanism
AOD-9604 (Anti-Obesity Drug 9604) is a 16-amino-acid synthetic peptide corresponding to residues 177–191 of human growth hormone (the C-terminal end), with a modification (tyrosine added to the N-terminus to support synthesis stability).
The development hypothesis was based on observations that the fat-mobilization effects of GH appear to be mediated by a different domain of the molecule than the growth-promoting and insulin-antagonizing effects. By administering only the C-terminal fragment, the theory went, you could get the lipolytic benefits without:
- The diabetogenic effects of full-length GH (impaired insulin sensitivity)
- The growth-promoting effects (concerning for chronic exposure)
- The IGF-1 elevation (cancer-promotion concern)
The mechanism by which AOD-9604 acts on adipose tissue is not fully characterized at the receptor level. It does not bind the GH receptor with significant affinity, suggesting it works through a distinct (and not fully identified) pathway. Some animal data points to direct effects on β-adrenergic signaling and lipolytic enzyme regulation in adipocytes.
Half-life is short (~30 minutes); it does not produce the characteristic IGF-1 elevation seen with GH or GHRH/GHRP analogs.
What the evidence shows
Phase 2 (Heffernan et al, Eur J Endocrinol 2001 and follow-up):
A 12-week trial in obese adults compared AOD-9604 (multiple doses, daily subcutaneous) to placebo. Results showed:
- Modest but statistically significant weight loss versus placebo at higher doses
- No significant changes in IGF-1, insulin sensitivity, or glucose tolerance
- Reasonable safety profile
This was the basis for advancing to Phase 3.
Phase 3 program (mid-2000s):
Metabolic Pharmaceuticals (Australian biotech, the developer) initiated Phase 3 trials and then discontinued the program. The published rationale is sparse; the most likely explanation is that the effect sizes in larger trials did not justify approval, or commercial considerations (a small biotech competing against forthcoming GLP-1 therapies) led to strategic discontinuation.
Subsequent evidence:
- AOD-9604 was repositioned for osteoarthritis — small clinical trial showed signal, but the program did not advance to approval
- Several smaller studies in mixed indications, none producing approval-level evidence
For body-composition use as marketed today:
The gray-market dose (300 mcg subcutaneous, often pre-cardio) is lower than the Phase 2 trial doses. There is no published evidence at the gray-market dose for body-composition outcomes.
Dosing literature
Phase 2 trial doses (Heffernan et al): Up to 1 mg/day subcutaneous
Gray-market protocols:
- 250–500 mcg subcutaneous once daily
- Often timed pre-cardio or pre-fasted-cardio under the theory of enhanced lipolysis during exercise
- Cycle structure: 8–12 weeks on, with off cycles
The Phase 2 effect sizes at higher doses were modest. Whether the lower gray-market doses produce meaningful effect is unstudied.
Risks and adverse events
Reported in Phase 2 and gray-market use:
- Generally well-tolerated acute profile
- Injection-site reactions
- Mild headache
- Mild fatigue
- Hunger changes (variable)
Notable absence:
- No significant IGF-1 elevation (this is the development premise and appears to hold)
- No diabetogenic effect (also consistent with the development premise)
- No GH-axis-typical effects (carpal tunnel, joint pain, edema)
This is a relatively clean acute safety profile for a peptide marketed for body composition.
Long-term concerns:
The mechanism of action is not fully characterized. “We don’t know exactly how it works” is a flag for chronic-use safety prediction. The Phase 3 abandonment also means we don’t have multi-year safety data that approval would have required.
Quality concerns:
The 16-amino-acid sequence is short and synthesizable. Mass-spec verification of gray-market AOD-9604 is uncommon; the typical research-peptide-channel quality concerns apply.
Regulatory status
| Region | Status | Notes |
|---|---|---|
| United States | Not approved | Phase 3 abandoned; no current submission. |
| European Union | Not approved | |
| United Kingdom | Not approved | |
| Australia | Not approved | The original developer is Australian; never advanced to approval. |
| WADA | Prohibited (S2 — Peptide Hormones) | Banned in competitive sport at all times. |
Where to get it
We do not route readers to a fulfillment partner for AOD-9604. The combination of unapproved regulatory status, abandoned Phase 3 development, and absence of efficacy data at the doses typically used puts it outside what we’ll endorse.
The cleaner safety profile compared to other GH-axis manipulators (no IGF-1 elevation, no GH-axis adverse effects) is a real distinguishing feature, but doesn’t substitute for efficacy evidence.
(See How we make money.)
References (selected)
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knockout mice. Endocrinology 2001. PubMed
- Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000.
- Stier H et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab 2013.
- Kim SH et al. AOD9604, a synthetic growth hormone fragment, exhibits anti-obesity activity. J Nutr Biochem 2010.
- Metabolic Pharmaceuticals investor disclosures (historical).
Quick Facts
| Also Known As | Anti-Obesity Drug-9604, Fragment 177-191 of human growth hormone, hGH 177-191 |
|---|---|
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe |
| Molecular Formula | C78H123N23O23S2 |
| Molecular Weight | 1815.1 Da |
| PubChem CID | 71300630 |
Research Parameters
| Half-Life | Unknown (Preclinical data suggests a relatively short half-life, but a specific value is not well-established in literature) |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in bacteriostatic water, the solution should be stored at 2-8°C and is typically stable for up to 28 days. Repeated freeze-thaw cycles should be avoided. |
| Solubility | Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for injection |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C, protect from light and moisture |
| Storage (Reconstituted) | 2-8°C (refrigerated), protected from light, use within 28 days |
| Typical Research Dose | 100-1000 mcg/kg (in animal research models) |
| Cycle Parameters | Daily subcutaneous injection, typically for 4-12 weeks in preclinical research protocols |
| Amino Acid Count | 16 |
Mechanism of Action
The precise mechanism of action of AOD-9604 is not fully elucidated but is distinct from that of full-length growth hormone. Research suggests it does not bind to the classical growth hormone receptor (GHR) and therefore does not stimulate insulin-like growth factor 1 (IGF-1) production, which is responsible for the growth-promoting effects of hGH. Instead, it appears to directly influence adipocytes (fat cells) and metabolic pathways.
Direct Lipolytic Stimulation: In vitro and in vivo studies indicate AOD-9604 directly stimulates lipolysis (breakdown of triglycerides into free fatty acids) in adipocytes. This effect is thought to be mediated through a β3-adrenergic receptor-like pathway or a novel, specific receptor interaction on fat cells, leading to increased hormone-sensitive lipase (HSL) activity.
Anti-Lipogenic Effects: The peptide may also inhibit lipogenesis (the formation of new fat). Research suggests it can reduce the activity of fatty acid synthase (FAS), a key enzyme in fat synthesis, thereby reducing the storage of new triglycerides in adipose tissue.
Metabolic Rate Modulation: Some evidence points to AOD-9604 increasing metabolic rate and promoting a shift in energy utilization towards fat oxidation, contributing to a reduction in overall fat mass in animal models of obesity.
Improved Insulin Sensitivity: Unlike hGH, which can induce insulin resistance, studies in animal models have reported that AOD-9604 may improve insulin sensitivity and glucose tolerance, potentially by reducing circulating free fatty acids and improving adipose tissue function.
Research Applications
Obesity and Weight Management: Preclinical research in diet-induced obese animal models has shown that AOD-9604 administration can lead to a reduction in body weight and fat mass without a loss of lean body mass. Studies report enhanced lipolysis and increased metabolic rate as contributing factors. The peptide's potential to act without stimulating the GH/IGF-1 axis makes it a candidate for investigating obesity treatments without associated growth-related side effects.
Metabolic Syndrome and Insulin Resistance: Research in rodent models of obesity and type 2 diabetes has indicated that AOD-9604 may improve markers of metabolic syndrome. Benefits observed include improved glucose tolerance, enhanced insulin sensitivity, and reduced hyperinsulinemia. These effects are hypothesized to result from reduced adiposity and a direct modulatory effect on adipose tissue biology.
Cartilage Repair and Osteoarthritis: Some in vitro and animal studies have explored the potential chondroprotective effects of AOD-9604. Research suggests it may stimulate the synthesis of proteoglycans and type II collagen in chondrocytes and exhibit anti-inflammatory properties in joint tissues, indicating a potential research avenue for cartilage repair and osteoarthritis.
Wound Healing: Preliminary in vitro studies have investigated the peptide's effects on fibroblasts, suggesting it may promote cell proliferation and migration. This has led to research into its potential application in models of wound healing and tissue repair, though this area is less developed than its metabolic research.
Safety & Side Effects
Based on available animal studies, AOD-9604 has been reported to have a favorable safety profile with no significant adverse effects observed at research doses. Specifically, studies have reported an absence of the growth-promoting, organomegaly, or diabetogenic effects associated with full-length hGH. No major systemic toxicity has been documented in these preclinical models.
Anecdotally, in contexts outside of controlled research, reported side effects are minimal and may include mild injection site reactions such as redness or itching. Theoretical concerns, based on its mechanism, are limited but would include the potential for excessive lipolysis leading to elevated free fatty acids, though this has not been a reported issue in studies. Its lack of interaction with the GH receptor suggests a low risk of acromegaly or cancer promotion related to the GH/IGF-1 axis.
Dosage Information
Disclaimer: The following information is derived from published preclinical research studies and is for research purposes only. It does not constitute clinical dosing guidelines.
In animal research studies (primarily rodent models of obesity), AOD-9604 has been administered via daily subcutaneous injection. Typical research dose ranges reported are between 100 mcg/kg and 1 mg/kg of body weight per day. The duration of treatment in these studies has varied from several weeks to a few months. In vitro studies utilize a wide range of concentrations depending on the cell type and assay.
References
Heffernan, M., et al. 'The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.' Endocrinology, 2001.
Ng, F.M., et al. 'Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.' Hormone Research, 2000.
Kirsten, V., et al. 'The lipolytic domain of human growth hormone (AOD9604) stimulates lipolysis in human adipose tissue in vitro.' Obesity Research & Clinical Practice, 2008.
Ehrnborg, C., et al. 'The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test.' Growth Hormone & IGF Research, 2003. (Contextual reference for GH fragments).
Ricci, M.R., et al. 'AOD9604 stimulates proteoglycan synthesis in bovine cartilage explants.' Osteoarthritis and Cartilage, 2007.
Ng, F.M., et al. 'Preliminary studies of a synthetic lipolytic domain of human growth hormone.' Proceedings of the Australian Society for Medical Research, 1998.